(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.24%.
Orchestra Biomed Holdings's earnings in 2025 is -$69,699,000.On average, 5 Wall Street analysts forecast OBIO's earnings for 2025 to be -$106,831,068, with the lowest OBIO earnings forecast at -$111,687,026, and the highest OBIO earnings forecast at -$95,500,500. On average, 5 Wall Street analysts forecast OBIO's earnings for 2026 to be -$89,889,172, with the lowest OBIO earnings forecast at -$97,658,704, and the highest OBIO earnings forecast at -$77,695,322.
In 2027, OBIO is forecast to generate -$83,090,831 in earnings, with the lowest earnings forecast at -$90,644,543 and the highest earnings forecast at -$75,537,119.